For the twelve months ended Aug 31, 2026, Nurix Therapeutics Inc. reported $701.94M of revenue and $294.88M of net income.
NRIX revenue was $673.06M in fiscal Q3 2026 (ended Aug 31, 2026), up about 85-fold from a year earlier and up about 74-fold from the prior quarter. For the full fiscal 2025 it was $83.98M, up 54.0% from fiscal 2024. Compound annual growth was +36.3% over 5 years. It rose in 4 of the last 6 fiscal years. Fiscal 2025 is the highest of the 7 fiscal years on file.
NRIX net income was $549.81M in fiscal Q3 2026 (ended Aug 31, 2026), compared with -$86.42M a year earlier. For the full fiscal 2025 it was -$264.46M, compared with -$193.57M in fiscal 2024.
NRIX diluted EPS was $4.73 in fiscal Q3 2026 (ended Aug 31, 2026), compared with -$1.03 a year earlier. For the full fiscal 2025 it was -$3.05, compared with -$2.88 in fiscal 2024.
NRIX free cash flow was $614.24M in fiscal Q3 2026 (ended Aug 31, 2026), compared with -$60.10M a year earlier. For the full fiscal 2025 it was -$263.47M, compared with -$181.86M in fiscal 2024.
| Line item | Nov 30, 2025 | Nov 30, 2024 | Nov 30, 2023 | Nov 30, 2022 | Nov 30, 2021 | Nov 30, 2020 | Nov 30, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $83.98M | $54.55M | $76.99M | $38.63M | $29.75M | $17.82M | $31.11M |
| Research and development | $316.90M | $221.63M | $189.15M | $184.50M | $116.43M | $66.49M | $45.02M |
| Selling, general and admin | $52.74M | $45.94M | $42.90M | $38.00M | $31.20M | $16.31M | $8.33M |
| Operating income | -$285.67M | -$213.03M | -$155.06M | -$183.87M | -$117.89M | -$64.98M | -$22.24M |
| Pre-tax income | -$263.70M | -$193.30M | -$143.95M | -$180.36M | -$117.06M | -$63.78M | -$21.46M |
| Income tax | $760.0K | $270.0K | $0 | $0 | $131.0K | -$20.54M | $239.0K |
| Net income | -$264.46M | -$193.57M | -$143.95M | -$180.36M | -$117.19M | -$43.24M | -$21.70M |
| EPS, basic | -$3.05 | -$2.88 | -$2.65 | -$3.71 | -$2.73 | -$2.76 | -$6.59 |
| EPS, diluted | -$3.05 | -$2.88 | -$2.65 | -$3.71 | -$2.73 | -$2.76 | -$6.59 |
| Diluted shares | 86.7M | 67.1M | 54.3M | 48.6M | 42.9M | 15.7M | 3.3M |
| Line item | Nov 30, 2025 | Nov 30, 2024 | Nov 30, 2023 | Nov 30, 2022 | Nov 30, 2021 | Nov 30, 2020 | Nov 30, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $246.96M | $110.90M | $54.63M | $64.47M | $80.51M | $119.36M | $34.82M |
| Short-term investments | - | - | - | $244.67M | $215.21M | $161.79M | $2.90M |
| Receivables | $0 | $0 | - | $0 | $6.00M | - | - |
| Current assets | $606.82M | $619.39M | $295.50M | $318.45M | $311.12M | $298.43M | $39.35M |
| Total assets | $688.13M | $669.34M | $355.60M | $416.76M | $476.77M | $396.34M | $44.05M |
| Current liabilities | $86.47M | $95.85M | $86.96M | $70.66M | $66.26M | $44.54M | $16.14M |
| Total liabilities | $149.39M | $142.35M | $155.10M | $113.06M | $134.47M | $106.07M | $53.57M |
| Shareholders' equity | $538.75M | $526.99M | $200.49M | $303.70M | $342.30M | $290.27M | -$57.71M |
| Line item | Nov 30, 2025 | Nov 30, 2024 | Nov 30, 2023 | Nov 30, 2022 | Nov 30, 2021 | Nov 30, 2020 | Nov 30, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$249.47M | -$172.58M | -$81.36M | -$159.81M | -$84.36M | -$80.0K | $601.0K |
| Capital expenditures | $14.00M | $9.27M | $8.40M | $12.24M | $5.66M | $4.55M | $1.65M |
| Free cash flow | -$263.47M | -$181.86M | -$89.77M | -$172.05M | -$90.03M | -$4.63M | -$1.05M |
| Investing cash flow | $147.85M | -$257.71M | $68.30M | $27.20M | -$108.25M | -$254.40M | $8.50M |
| Financing cash flow | $238.64M | $485.67M | $3.22M | $117.19M | $153.88M | $339.02M | $126.0K |
| Stock-based compensation | $37.97M | $33.93M | $33.67M | $28.13M | $15.80M | $4.30M | $510.0K |
| Depreciation and amortization | $8.74M | $9.32M | $7.53M | $5.35M | $2.79M | $2.18M | $2.35M |
| Line item | Nov 30, 2025 | Nov 30, 2024 | Nov 30, 2023 | Nov 30, 2022 | Nov 30, 2021 | Nov 30, 2020 | Nov 30, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 54.0% | -29.1% | 99.3% | 29.8% | 66.9% | -42.7% | - |
| Operating margin | -340.2% | -390.5% | -201.4% | -476.0% | -396.3% | -364.7% | -71.5% |
| Net margin | -314.9% | -354.9% | -187.0% | -466.9% | -393.9% | -242.7% | -69.7% |
| Free cash flow margin | -313.7% | -333.4% | -116.6% | -445.4% | -302.6% | -26.0% | -3.4% |
| Return on equity | -49.1% | -36.7% | -71.8% | -59.4% | -34.2% | -14.9% | - |
| Return on assets | -38.4% | -28.9% | -40.5% | -43.3% | -24.6% | -10.9% | -49.3% |
| Current ratio | 7.02 | 6.46 | 3.40 | 4.51 | 4.70 | 6.70 | 2.44 |
| Line item | Aug 31, 2026 | May 31, 2026 | Feb 28, 2026 | Nov 30, 2025 | Aug 31, 2025 | May 31, 2025 | Feb 28, 2025 | Nov 30, 2024 | Aug 31, 2024 | May 31, 2024 | Feb 29, 2024 | Nov 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $673.06M | $9.04M | $6.25M | $13.58M | $7.89M | $44.06M | $18.45M | $13.28M | $12.59M | $12.09M | $16.59M | $15.16M |
| Research and development | $79.26M | $87.65M | $84.14M | $83.02M | $86.12M | $78.10M | $69.66M | $67.22M | $55.48M | $48.92M | $50.01M | $49.71M |
| Selling, general and admin | $34.35M | $15.59M | $14.61M | $13.65M | $13.16M | $14.28M | $11.65M | $10.72M | $11.72M | $11.71M | $11.80M | $10.78M |
| Operating income | $559.45M | -$94.20M | -$92.50M | -$83.09M | -$91.39M | -$48.32M | -$62.86M | -$64.66M | -$54.61M | -$48.54M | -$45.22M | -$45.33M |
| Pre-tax income | $563.41M | -$89.81M | -$87.17M | -$78.22M | -$86.42M | -$42.70M | -$56.35M | -$58.54M | -$48.87M | -$44.46M | -$41.43M | -$41.96M |
| Income tax | $13.61M | -$271.0K | $0 | $0 | $0 | $760.0K | $0 | $8.0K | $82.0K | $90.0K | $90.0K | $0 |
| Net income | $549.81M | -$89.53M | -$87.17M | -$78.22M | -$86.42M | -$43.46M | -$56.35M | -$58.55M | -$48.96M | -$44.55M | -$41.52M | -$41.96M |
| EPS, basic | $4.93 | -$0.81 | -$0.79 | -$0.83 | -$1.03 | -$0.52 | -$0.67 | - | -$0.67 | -$0.71 | -$0.76 | -$0.77 |
| EPS, diluted | $4.73 | -$0.81 | -$0.79 | -$0.83 | -$1.03 | -$0.52 | -$0.67 | - | -$0.67 | -$0.71 | -$0.76 | -$0.77 |
| Diluted shares | 116.2M | 111.1M | 110.1M | - | 84.2M | 83.9M | 83.6M | - | 72.8M | 62.4M | 54.9M | - |
| Line item | Aug 31, 2026 | May 31, 2026 | Feb 28, 2026 | Nov 30, 2025 | Aug 31, 2025 | May 31, 2025 | Feb 28, 2025 | Nov 30, 2024 | Aug 31, 2024 | May 31, 2024 | Feb 29, 2024 | Nov 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $720.24M | $67.69M | $71.19M | $246.96M | $78.44M | $84.26M | $75.92M | $110.90M | $99.04M | $116.79M | $49.81M | $54.63M |
| Receivables | $20.00M | - | - | $0 | - | $19.00M | - | $0 | - | - | - | - |
| Current assets | $1.10B | $456.48M | $554.39M | $606.82M | $440.60M | $515.33M | $563.70M | $619.39M | $456.04M | $450.22M | $250.97M | $295.50M |
| Total assets | $1.20B | $535.54M | $636.13M | $688.13M | $522.47M | $591.55M | $615.04M | $669.34M | $513.60M | $511.03M | $312.67M | $355.60M |
| Current liabilities | $130.74M | $72.02M | $92.20M | $86.47M | $82.35M | $75.61M | $89.99M | $95.85M | $86.30M | $80.78M | $87.62M | $86.96M |
| Total liabilities | $226.99M | $132.91M | $155.24M | $149.39M | $150.22M | $143.95M | $134.13M | $142.35M | $136.74M | $140.34M | $143.93M | $155.10M |
| Shareholders' equity | $968.31M | $402.63M | $480.89M | $538.75M | $372.25M | $447.60M | $480.92M | $526.99M | $376.86M | $370.69M | $168.75M | $200.49M |
| Line item | Aug 31, 2026 | May 31, 2026 | Feb 28, 2026 | Nov 30, 2025 | Aug 31, 2025 | May 31, 2025 | Feb 28, 2025 | Nov 30, 2024 | Aug 31, 2024 | May 31, 2024 | Feb 29, 2024 | Nov 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $615.63M | -$96.57M | -$71.91M | -$67.83M | -$57.38M | -$63.16M | -$61.09M | -$48.75M | -$42.18M | -$39.70M | -$41.95M | $26.69M |
| Capital expenditures | $1.39M | $1.94M | $1.04M | $5.13M | $2.71M | $2.67M | $3.48M | $2.10M | $2.35M | $1.94M | $2.88M | $2.58M |
| Free cash flow | $614.24M | -$98.51M | -$72.96M | -$72.96M | -$60.10M | -$65.84M | -$64.57M | -$50.86M | -$44.52M | -$41.64M | -$44.84M | $24.10M |
| Investing cash flow | $31.58M | $93.00M | -$123.83M | $346.0K | $50.48M | $71.50M | $25.53M | -$140.82M | -$21.34M | -$131.07M | $35.51M | -$14.37M |
| Financing cash flow | $5.16M | $66.0K | $19.98M | $236.01M | $1.16M | $6.0K | $1.47M | $200.52M | $45.77M | $237.75M | $1.62M | $7.0K |
| Stock-based compensation | $10.78M | $11.39M | $9.40M | $9.09M | $9.77M | $10.38M | $8.72M | $8.51M | $8.75M | $8.85M | $7.82M | $8.02M |
| Depreciation and amortization | $2.14M | $2.25M | $2.20M | $2.12M | $2.03M | $2.24M | $2.35M | $2.55M | $2.39M | $2.33M | $2.04M | $1.93M |
| Line item | Aug 31, 2026 | May 31, 2026 | Feb 28, 2026 | Nov 30, 2025 | Aug 31, 2025 | May 31, 2025 | Feb 28, 2025 | Nov 30, 2024 | Aug 31, 2024 | May 31, 2024 | Feb 29, 2024 | Nov 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 8426.3% | -79.5% | -66.1% | 2.2% | -37.3% | 264.3% | 11.3% | -12.4% | -31.8% | -60.6% | 30.7% | 123.5% |
| Operating margin | 83.1% | -1041.7% | -1479.4% | -612.0% | -1157.7% | -109.7% | -340.7% | -486.7% | -433.8% | -401.4% | -272.6% | -299.1% |
| Net margin | 81.7% | -990.1% | -1394.3% | -576.1% | -1094.8% | -98.7% | -305.4% | -440.7% | -388.9% | -368.4% | -250.3% | -276.8% |
| Free cash flow margin | 91.3% | -1089.3% | -1167.0% | -537.4% | -761.3% | -149.4% | -349.9% | -382.8% | -353.7% | -344.4% | -270.3% | 159.0% |
| Current ratio | 8.44 | 6.34 | 6.01 | 7.02 | 5.35 | 6.82 | 6.26 | 6.46 | 5.28 | 5.57 | 2.86 | 3.40 |
Source: XBRL data Nurix Therapeutics Inc. files with the SEC, latest filing dated Oct 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NRIX | $701.94M | +738.8% | $294.88M | 42.0% | $1.76B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |